自身免疫性肝炎诊治——病理必不可缺

王丽; 杨永峰

doi:10.3969/j.issn.1001-5256.2023.03.004

自身免疫性肝炎诊治——病理必不可缺

DOI: 10.3969/j.issn.1001-5256.2023.03.004

王丽¹,
杨永峰^2, , ,

1.
南京中医药大学，南京 210029
2.
南京中医药大学附属南京医院(南京市第二医院) 肝病科，南京 210029

基金项目:

国家自然科学基金 (81970454)

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：王丽负责检索文献，撰写文章；杨永峰负责设计文章框架，文献检索策略，修改和审核文章。

详细信息

通信作者:
杨永峰，yyf1997@163.com(ORCID: 0000-0002-3214-0038)

计量
- 文章访问数: 742
- HTML全文浏览量: 172
- PDF下载量: 215
- 被引次数: 0
出版历程
- 收稿日期: 2022-12-31
- 录用日期: 2023-02-07
- 出版日期: 2023-03-20

Diagnosis and treatment of autoimmune hepatitis: The indispensable role of pathology

Li WANG¹,
Yongfeng YANG^{2
, ,
,}

1.
Nanjing University of Chinese Medicine, Nanjing 210029, China
2.
Department of Hepatology, Nanjing Hospital Affiliated to Nanjing University of Chinese Medicine & Nanjing Second Hospital, Nanjing 210029, China

Research funding:

National Natural Science Foundation of China (81970454)

More Information

Corresponding author: YANG Yongfeng, yyf1997@163.com (ORCID: 0000-0002-3214-0038)

摘要

摘要: 自身免疫性肝炎现已成为国内主要的非感染性肝炎类型，本文从临床及病理角度归纳并论述了其特征性表现及诊治现状，总结出病理组织学在自身免疫性肝炎诊治中必不可缺的地位。
- 肝炎, 自身免疫性 /
- 病理学, 临床 /
- 诊断
Abstract: Autoimmune hepatitis has become the main type of non-infectious hepatitis in China. This article summarizes its characteristic manifestations and the current status of diagnosis and treatment and points out that pathological histology plays an indispensable role in the diagnosis and treatment of autoimmune hepatitis.
- Hepatitis, Autoimmune /
- Pathology, Clinical /
- Diagnosis

HTML全文

图 1 慢性发病AIH病理特征(HE染色)

注：a, 界面性肝炎(×10)；b, 浆细胞浸润，箭头示浆细胞(×40)；c, 玫瑰花结(×40)；d, 箭头示淋巴细胞穿入(×40)。

Figure 1. Pathological characteristics of chronic AIH (HE staining)

下载: 全尺寸图片幻灯片

表 1 依据小叶及汇管区炎症表现的AIH诊断标准

Table 1. Histological criteria of AIH based on lobular and portal inflammation

项目	汇管区炎	小叶炎
极可能的AIH	汇管区淋巴-浆细胞浸润+以下1种或2种特征: (1)轻度以上界面炎; (2)轻度以上小叶炎排除提示其他肝病的组织学特征	轻度以上小叶炎(伴或不伴小叶中心性坏死)+以下至少1种特征: (1)淋巴-浆细胞浸润; (2)界面炎; (3)汇管区纤维化排除提示其他肝病的组织学特征
可能的AIH	汇管区淋巴-浆细胞浸润 ·不具有上述1种或2种极可能的特征之一 ·排除提示其他肝病的组织学特征或 ·具有上述1种或2种极可能的特征 ·存在提示其他肝病的组织学特征	任何小叶炎(伴或不伴小叶中心性坏死) ·不具有上述1~3种极可能的特征之一 ·排除提示其他肝病的组织学特征或 ·具有上述任何1种极可能的特征 ·存在提示其他肝病的组织学特征
不可能的AIH	汇管区炎 ·不具有上述1种或2种极可能的特征之一 ·存在提示其他肝病的组织学特征	小叶型肝炎 ·不具有上述任何极可能的特征 ·存在提示其他肝病的组织学特征

下载: 导出CSV

参考文献(24)

[1]	LIU HL, YANG YF, XIONG QF, et al. Etiological analysis of hepatopathy of unknown etiology in 470 cases undergoing routine liver biopsy examination[J]. Chin J Hepatol, 2019, 27(11): 885-889. DOI: 10.3760/cma.j.issn.1007-3418.2019.11.012. 刘红丽, 杨永峰, 熊清芳, 等. 470例行肝穿刺活组织检查的不明原因肝病的病因分析[J]. 中华肝脏病杂志, 2019, 27(11): 885-889. DOI: 10.3760/cma.j.issn.1007-3418.2019.11.012.
[2]	ZHANG HY, MA X. Diagnosis and management of autoimmune hepatitis with acute presentation[J]. Chin J Hepatol, 2012, 20(5): 396-397. DOI: 10.3760/cma.j.issn.1007-3418.2012.05.021. 张海燕, 马雄. 急性起病自身免疫性肝炎的诊断与治疗[J]. 中华肝脏病杂志, 2012, 20(5): 396-397. DOI: 10.3760/cma.j.issn.1007-3418.2012.05.021.
[3]	LI YN, MA H, ZHOU L, et al. Autoimmune hepatitis-related cirrhosis: clinical features and effectiveness of immunosuppressive treatment in chinese patients[J]. Chin Med J (Engl), 2016, 129(20): 2434-2440. DOI: 10.4103/0366-6999.191760.
[4]	VILLALTA D, GIROLAMI E, ALESSIO MG, et al. Autoantibody profiling in a cohort of pediatric and adult patients with autoimmune hepatitis[J]. J Clin Lab Anal, 2016, 30(1): 41-46. DOI: 10.1002/jcla.21813.
[5]	GORDON V, ADHIKARY R, APPLEBY V, et al. Diagnosis, presentation and initial severity of Autoimmune Hepatitis (AIH) in patients attending 28 hospitals in the UK[J]. Liver Int, 2018, 38(9): 1686-1695. DOI: 10.1111/liv.13724.
[6]	SEBODE M, WEILER-NORMANN C, LIWINSKI T, et al. Autoantibodies in autoimmune liver disease-clinical and diagnostic relevance[J]. Front Immunol, 2018, 9: 609. DOI: 10.3389/fimmu.2018.00609.
[7]	TERZIROLI BERETTA-PICCOLI B, MIELI-VERGANI G, et al. Autoimmune hepatitis: Serum autoantibodies in clinical practice[J]. Clin Rev Allergy Immunol, 2022, 63(2): 124-137. DOI: 10.1007/s12016-021-08888-9.
[8]	GATSELIS NK, ZACHOU K, KOUKOULIS GK, et al. Autoimmune hepatitis, one disease with many faces: etiopathogenetic, clinico-laboratory and histological characteristics[J]. World J Gastroenterol, 2015, 21(1): 60-83. DOI: 10.3748/wjg.v21.i1.60.
[9]	YANG XJ, YANG YF, ZHONG YD. The value of serum immunoglobulin and autoantibodies in the diagnosis of autoimmune hepatitis[J]. Chin Hepatol, 2018, 23(12): 1084-1086. DOI: 10.14000/j.cnki.issn.1008-1704.2018.12.012. 杨小娇, 杨永峰, 钟艳丹. 血清免疫球蛋白与自身抗体检测在自身免疫性肝炎诊断中的价值[J]. 肝脏, 2018, 23(12): 1084-1086. DOI: 10.14000/j.cnki.issn.1008-1704.2018.12.012.
[10]	MIAO Q, CHEN XY. Liver histopathological diagnosis of autoimmune hepatitis[J]. J Clin Hepatol, 2020, 36(4): 728-730. DOI: 10.3969/j.issn.1001-5256.2020.04.003. 苗琪, 陈晓宇. 自身免疫性肝炎的肝组织病理学诊断[J]. 临床肝胆病杂志, 2020, 36(4): 728-730. DOI: 10.3969/j.issn.1001-5256.2020.04.003.
[11]	NGUYEN CANH H, HARADA K, OUCHI H, et al. Acute presentation of autoimmune hepatitis: a multicentre study with detailed histological evaluation in a large cohort of patients[J]. J Clin Pathol, 2017, 70(11): 961-969. DOI: 10.1136/jclinpath-2016-204271.
[12]	AIZAWA Y, ABE H, SUGITA T, et al. Centrilobular zonal necrosis as a hallmark of a distinctive subtype of autoimmune hepatitis[J]. Eur J Gastroenterol Hepatol, 2016, 28(4): 391-397. DOI: 10.1097/MEG.0000000000000545.
[13]	WANG PS, WANG JY, HU XQ, et al. Clinical and histopathologic features of drug-induced autoimmune hepatitis[J]. Chin J Dig, 2014, 34(2): 105-108. DOI: 10.3760/cma.j.issn.0254-1432.2014.02.008. 王丕胜, 王吉耀, 胡锡琪, 等. 药物诱导的自身免疫性肝炎的临床和病理特点[J]. 中华消化杂志, 2014, 34(2): 105-108. DOI: 10.3760/cma.j.issn.0254-1432.2014.02.008.
[14]	BJÖRNSSON ES, NAVARRO VJ, CHALASANI N. Liver injury following tinospora cordifolia consumption: Drug-Induced AIH, or de novo AIH?[J]. J Clin Exp Hepatol, 2022, 12(1): 6-9. DOI: 10.1016/j.jceh.2021.11.014.
[15]	FEBRES-ALDANA CA, ALGHAMDI S, KRISHNAMURTHY K, et al. Liver fibrosis helps to distinguish autoimmune hepatitis from DILI with autoimmune features: A review of twenty cases[J]. J Clin Transl Hepatol, 2019, 7(1): 21-26. DOI: 10.14218/JCTH.2018.00053.
[16]	TSUTSUI A, HARADA K, TSUNEYAMA K, et al. Histopathological analysis of autoimmune hepatitis with "acute" presentation: Differentiation from drug-induced liver injury[J]. Hepatol Res, 2020, 50(9): 1047-1061. DOI: 10.1111/hepr.13532.
[17]	ALVAREZ F, BERG PA, BIANCHI FB, et al. International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis[J]. J Hepatol, 1999, 31(5): 929-938. DOI: 10.1016/s0168-8278(99)80297-9.
[18]	HENNES EM, ZENIYA M, CZAJA AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis[J]. Hepatology, 2008, 48(1): 169-176. DOI: 10.1002/hep.22322.
[19]	QIU D, WANG Q, WANG H, et al. Validation of the simplified criteria for diagnosis of autoimmune hepatitis in Chinese patients[J]. J Hepatol, 2011, 54(2): 340-347. DOI: 10.1016/j.jhep.2010.06.032.
[20]	LOHSE AW, SEBODE M, BHATHAL PS, et al. Consensus recommendations for histological criteria of autoimmune hepatitis from the International AIH Pathology Group: Results of a workshop on AIH histology hosted by the European Reference Network on Hepatological Diseases and the European Society of Pathology: Results of a workshop on AIH histology hosted by the European Reference Network on Hepatological Diseases and the European Society of Pathology[J]. Liver Int, 2022, 42(5): 1058-1069. DOI: 10.1111/liv.15217.
[21]	HARADA K, HIEP NC, OHIRA H. Challenges and difficulties in pathological diagnosis of autoimmune hepatitis[J]. Hepatol Res, 2017, 47(10): 963-971. DOI: 10.1111/hepr.12931.
[22]	Chinese Society of Hepatology, Chinese Medical Association. Guidelines on the diagnosis and management of autoimmune hepatitis (2021)[J]. J Clin Hepatol, 2022, 38(1): 42-49. DOI: 10.3760/cma.j.cn112138-20211112-00796. 中华医学会肝病学分会. 自身免疫性肝炎诊断和治疗指南(2021)[J]. 临床肝胆病杂志, 2022, 38(1): 42-49. DOI: 10.3760/cma.j.cn112138-20211112-00796.
[23]	AL-CHALABI T, HENEGHAN MA. Remission in autoimmune hepatitis: what is it, and can it ever be achieved?[J]. Am J Gastroenterol, 2007, 102(5): 1013-1015. DOI: 10.1111/j.1572-0241.2007.01147.x.
[24]	HARRISON L, GLEESON D. Stopping immunosuppressive treatment in autoimmune hepatitis (AIH): Is it justified (and in whom and when)?[J]. Liver Int, 2019, 39(4): 610-620. DOI: 10.1111/liv.14051.